GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

A Study on the Immune Response and Safety of an Adjuvanted Human Papillomavirus Vaccine When Given to Healthy Women 16 to 26 Years of Age

Phase 1

Completed

Conditions: Cervical Intraepithelial Neoplasia

Interventions: Biological: HPV9 High formulation
Biological: HPV9 Medium formulation
Biological: HPV9 Low formulation
Biological: Gardasil 9

First Posted Date: 2022-08-11

Last Posted Date: 2025-02-03

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 1080

Registration Number: NCT05496231

Locations: 🇵🇱
GSK Investigational Site, Warszawa, Poland

A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella and Typhoid Fever

Phase 1

Recruiting

Conditions: Salmonella Infections

Interventions: Biological: Invasive nontyphoidal Salmonella-generalized modules for membrane antigens vaccine (iNTS-GMMA) full dose
Biological: Invasive nontyphoidal Salmonella-typhoid conjugate vaccine (iNTS-TCV) full dose
Biological: Invasive nontyphoidal Salmonella-typhoid conjugate vaccine (iNTS-TCV) low dose
Biological: Invasive nontyphoidal Salmonella-generalized modules for membrane antigens vaccine (iNTS-GMMA) low dose
Drug: Placebo
Biological: GSK's Meningococcal A, C, Y and W-135 conjugate vaccine
Other: Saline
Biological: Typhoid conjugate vaccine (TCV) low dose
Biological: Typhoid conjugate vaccine (TCV) full dose
Combination Product: GSK's Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine
Combination Product: Sanofi Pasteur's Typhoid Vi polysaccharide vaccine

First Posted Date: 2022-07-29

Last Posted Date: 2024-02-22

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 155

Registration Number: NCT05480800

Locations: 🇲🇼
GSK Investigational Site, Blantyre 3, Malawi

Safety and Immunogenicity Study of a Booster Dose of the Investigational CV0501 mRNA COVID-19 Vaccine in Adults at Least 18 Years Old

Phase 1

Completed

Conditions: COVID-19
SARS-CoV-2

Interventions: Biological: CV0501 (12 μg)
Biological: CV0501 (25 μg)
Biological: CV0501 (50 μg)
Biological: CV0501 (100 μg)
Biological: CV0501 (200 μg)
Biological: CV0501 (6 μg)
Biological: CV0501 (3 μg)
Biological: CV0501 (75 μg)
Biological: CV0501 (150 μg)

First Posted Date: 2022-07-28

Last Posted Date: 2025-02-21

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 185

Registration Number: NCT05477186

Locations: 🇵🇭
GSK Investigational Site, Iloilo City, Philippines

Linerixibat Compassionate Use for Cholestatic Pruritus Adult Patients With Primary Biliary Cholangitis (PBC)

Conditions: Pruritus

First Posted Date: 2022-07-07

Last Posted Date: 2025-02-27

Lead Sponsor: GlaxoSmithKline

Registration Number: NCT05448170

A Study on the Safety, Reactogenicity and Immune Response of a Vaccine Against Influenza in Healthy Younger and Older Adults

Phase 1

Completed

Conditions: Influenza, Human

Interventions: Biological: GSK4382276A Dose level 11
Biological: GSK4382276A Dose level 2
Biological: GSK4382276A Dose level 4
Biological: GSK4382276A Dose level 6
Biological: GSK4382276A Dose level 9
Biological: GSK4382276A Dose level 7
Biological: GSK4382276A Dose level 8
Biological: GSK4382276A Dose level 10
Combination Product: FDQ21A-NH
Biological: GSK4382276A Dose level 1
Combination Product: FDQ22A-NH
Biological: GSK4382276A Dose level 3